Ferumoxsil is not approved for marketing in the United States by the U.S. Food and Drug Administration. No information is available on the clinical use of ferumoxsil during breastfeeding. If ferumoxsil is required by the mother, it is not a reason to discontinue breastfeeding.[1] However, since there is no published experience with ferumoxsil during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Cova MA, Stacul F, Quaranta R et al. Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy. Eur Radiol. 2014;24:2012-22. [PubMed: 24838733]
Substance Identification
Substance Name
Ferumoxsil
CAS Registry Number
171544-35-7
Drug Class
Breast Feeding
Lactation
Contrast Media
Diagnostic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
